Sutent Approval History
FDA Approved: Yes (First approved January 26, 2006)
Brand name: Sutent
Generic name: sunitinib malate
Dosage form: Capsules
Company: Pfizer Inc.
Treatment for: Gastrointestinal Stromal Tumor, Renal Cell Carcinoma, Pancreatic Cancer
Sutent (sunitinib malate) is an oral multi-kinase inhibitor indicated for the treatment of gastrointestinal stromal tumors, advanced renal cell carcinoma (RCC), adjuvant treatment of patients at high risk of recurrent RCC following nephrectomy, and the treatment of pancreatic neuroendocrine tumors.
Development History and FDA Approval Process for Sutent
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.